Incyte Corporation provided revenue guidance for 2024. For the year the company expects Jakafi net product revenues of $2,690 million to $2,750 million. The company expects other Hematology/Oncology net product revenues of $325 million - $360 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.79 USD | +0.86% | +0.84% | -7.96% |
23/05 | Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target | MT |
21/05 | Incyte Acquires 2 Office Buildings in Delaware | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.96% | 1.3TCr | |
-2.29% | 8.99TCr | |
-3.95% | 3.76TCr | |
-13.07% | 3.28TCr | |
+63.05% | 2.65TCr | |
-22.14% | 1.43TCr | |
-9.33% | 1.19TCr | |
-46.33% | 1.08TCr | |
+5.77% | 911.12Cr | |
-17.66% | 732.39Cr |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation Provides Revenue Guidance for 2024